Evidence map›Paper›PMID 25143296›Full record

Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2014

Organic cation transporter variation and response to smoking cessation therapies.

Andrew W Bergen, Harold S Javitz, Ruth Krasnow, Martha Michel, Denise Nishita, David V Conti, Christopher K Edlund, Pui-Yan Kwok, Jennifer B McClure, Richard B Kim and 5 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Genetic and Epigenetic Regulation of Organic Cation Transporters.Handbook of experimental pharmacology · 2021
    Review
  12. Organic Cation Transporters in Psychiatric Disorders.Handbook of experimental pharmacology · 2021
    Article
  13. Interaction of rs316019 variants of SLC22A2 with metformin and other drugs- anJournal, genetic engineering & biotechnology · 2018
    Article
  14. Article
  15. Pharmacogenetic Optimization of Smoking Cessation Treatment.Trends in pharmacological sciences · 2017
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Andrew W BergenCenter for Health Sciences, SRI International, Menlo Park, CA; andrew.bergen@sri.com.
Harold S JavitzCenter for Health Sciences, SRI International, Menlo Park, CA;
Ruth KrasnowCenter for Health Sciences, SRI International, Menlo Park, CA;
Martha MichelCenter for Health Sciences, SRI International, Menlo Park, CA;
Denise NishitaCenter for Health Sciences, SRI International, Menlo Park, CA;
David V ContiDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA;
Christopher K EdlundDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA; BioRealm, LLC, Monument, CO;
Pui-Yan KwokDepartment of Dermatology, University of California, San Francisco, CA;
Jennifer B McClureGroup Health Research Institute, Seattle, WA;
Richard B KimDepartment of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada;
Sharon M HallDepartment of Psychiatry, University of California, San Francisco, CA;
Rachel F TyndaleCentre for Addiction and Mental Health, and Departments of Psychiatry, Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada;
Timothy B BakerCenter for Tobacco Research and Intervention, University of Wisconsin, Madison, WI;
Neal L BenowitzDepartments of Medicine and Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA;
Gary E SwanStanford Prevention Research Center, Stanford University School of Medicine, Palo Alto, CA.
SRI International · USUniversity of California, San Francisco · USUniversity of Southern California · USCentre for Addiction and Mental Health · CAKaiser Permanente Washington Health Research Institute · USStanford University · USUniversity of Wisconsin–Madison · USWestern University · CA

Funding

TREATMENTS FOR COMPLEX PATIENTS IN NEW SETTINGSP50DA009253 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 1994 to 2005
$9.7M
RELAPSE: LINKING SCIENCE AND PRACTICEP50CA084724 · UNIVERSITY OF WISCONSIN MADISON · 1999 to 2003
$8.9M
Tobacco Dependence: Treatment and OutcomesP50DA019706 · UNIVERSITY OF WISCONSIN MADISON · 2004 to 2005
$3.4M
Maintaining Abstinence in Chronic Cigarette SmokersR01DA015732 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 2002 to 2005
$2.1M
PROJECT 1 (LEADERSHIP CORE)U01DA020830 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 2005 to 2005
$2.0M
Treatment of Nicotine Dependence in Health Care SettingR01CA071358 · SRI INTERNATIONAL · 1997 to 2005
$1.7M
PHARMACOKINETICS OF NICOTINE IN TWINSR01DA011170 · SRI INTERNATIONAL · 1998 to 2002
$1.5M
Leveraging the National Cancer Institute’s Cancer Center Cessation Initiative (C3I) Program to Evaluate and Transform Smoking Cessation Treatment in Cancer CareR35CA197573 · UNIVERSITY OF WISCONSIN-MADISON · 2025 to 2025
$932k
Treatment of Complex Patients: Emphasis on NicotineK05DA016752 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 2003 to 2005
$341k
Treating Tobacco Dependence in Inpatient PsychiatryK23DA018691 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 2005 to 2005
$138k
NCI NIH HHS K05 CA139871NCI NIH HHS P01 CA180945NCI NIH HHS P50 CA084724NCI NIH HHS P50 CA84724NCI NIH HHS R01 CA071358NCI NIH HHS R01S CA71358NIDA NIH HHS DA11170NIDA NIH HHS DA15732NIDA NIH HHS DA18691NIDA NIH HHS DA9253NIDA NIH HHS K05 DA016752NIDA NIH HHS K23 DA018691NIDA NIH HHS P50 DA009253NIDA NIH HHS P50 DA019706NIDA NIH HHS P50 DA19706NIDA NIH HHS R01 DA011170NIDA NIH HHS R01 DA015732NIDA NIH HHS R01S DA16752NIDA NIH HHS R21 DA033813NIDA NIH HHS R21 DA33813NIDA NIH HHS U01 DA020830NIDA NIH HHS U01 DA20830
6 · The paper itself

Abstract

introductionWe evaluated chr6q25.3 organic cation transporter gene (SLC22A1, SLC22A2, SLC22A3) variation and response to smoking cessation therapies. The corresponding proteins are low-affinity transporters of choline, acetylcholine and monoamines, and smoking cessation pharmacotherapies expressed in multiple tissues.

methodsWe selected 7 common polymorphisms for mega-regression analysis. We assessed additive model association of polymorphisms with 7-day point prevalence abstinence overall and by assigned pharmacotherapy at end of treatment and at 6 months among European-ancestry participants of 7 randomized controlled trials adjusted for demographic, population genetic, and trial covariates.

resultsInitial results were obtained in 6 trials with 1,839 participants. Nominally statistically significant associations of 2 SLC22A2 polymorphisms were observed: (1) with rs316019 at 6 months, overall ([c.808T>G; p.Ser270Ala], OR = 1.306, 95% CI = 1.034-1.649, p = .025), and among those randomized to nicotine replacement therapy (NRT) (OR = 1.784, 95% CI = 1.072-2.970, p = .026); and (2) with rs316006 (c.1502-529A>T) among those randomized to varenicline (OR = 1.420, 95% CI = 1.038-1.944, p = .028, OR = 1.362, 95% CI = 1.001-1.853, p = .04) at end of treatment and 6 months. Individuals randomized to NRT from a seventh trial were genotyped for rs316019; rs316019 was associated with a nominally statistically significant effect on abstinence overall at 6 months among 2,233 participants (OR = 1.249, 95% CI = 1.007-1.550, p = .043).

conclusionsThe functional OCT2 Ser270Ala polymorphism is nominally statistically significantly associated with abstinence among European-ancestry treatment-seeking smokers after adjustments for pharmacotherapy, demographics, population genetics, and without adjustment for multiple testing of 7 SNPs. Replication of these preliminary findings in additional randomized controlled trials of smoking cessation therapies and from multiple continental populations would describe another pharmacogenetic role for SLC22A2/OCT2.

Indexed as

AdultBenzazepinesFemaleGenetic VariationHumansMaleMiddle AgedOrganic Cation Transporter 2Organic Cation Transport ProteinsPolymorphism, Single NucleotideProspective StudiesQuinoxalinesSmokingSmoking CessationTobacco Use DisorderVareniclineBenzazepinesOrganic Cation Transporter 2Organic Cation Transport ProteinsQuinoxalinesSLC22A2 protein, humanVarenicline

Identifiers

PMID25143296
PMCPMC4296186
OpenAlexW2108338539

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.